- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04379518
Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients
Phase 1/2A Study of Rintatolimod and IFN Alpha Regimen in Cancer Patients With COVID-19
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To determine the safety of the combination of intravenous (i.v.) rintatolimod administered with or without i.v. IFN alpha (recombinant interferon alfa-2b [Intron A]) in patients with cancer with coronavirus disease 2019 (COVID-19).
II. Determine the kinetics of viral load in nasopharyngeal swabs in the course of treatment and Days 7 and 14.
SECONDARY OBJECTIVES:
I. To assess the efficacy of the treatment combination in patients with cancer with COVID-19.
II. Determine the kinetics of viral load in the peripheral blood in the course of treatment and Days 7 and 14.
III. Determine the kinetics of changes of the immune subsets and circulating inflammatory mediators (including C-reactive protein [CRP], cytokines, chemokines, interferons) in peripheral blood in the course of treatment and Days 7 and 14.
IV. Determine the induction of known mediators of antiviral immunity that include (myxovirus resistance gene, MxA; protein Kinase R (PKR); oligoadenylate synthetase-2 (OAS2); RNAse-L, IFN-stimulated gene-15 (ISG15); IFN-induced proteins with tetratricopeptide repeats (IFIT1) and IFN-inducible transmembrane protein 3 (IFITM3), TLR3, RIG-I, MDA5, IRF3, IRF7, in nasopharyngeal swabs material and blood cells of patients on all tiers of treatment.
OUTLINE: This is a phase I, dose-escalation study of recombinant interferon alfa-2b followed by a phase II study.
LEAD-IN PHASE: Patients receive rintatolimod IV over 2.5-3 hours on day 1 and day 3 (or 4).
Subsequent patients are randomized to 1 of 2 arms.
ARM I: Patients receive rintatolimod IV over 2.5-3 hours and recombinant interferon alfa-2b IV over 20 minutes on day 1 and on day 3 or 4 in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive standard of care.
EXPANSION COHORT: Patients are randomized to 1 of 2 arms.
ARM III: Patients receive rintatolimod IV over 2.5-3 hours once.
ARM IV: Patients receive standard of care.
Patients are followed up at days 7, 14 and 30 after initiation of the study regimen.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
Buffalo, New York, United States, 14263
- Roswell Park Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- INCLUSION CRITERIA (MAIN COHORT):
- Patients with cancer, with the exception of patients with active acute leukemia and allogeneic hematopoietic stem cell transplant recipients. Patients may be on active therapy or received therapy (e.g., chemotherapy, radiation or surgery) within 7 years. Patients with active cancer who have not yet been treated (e.g. newly diagnosed cancer or early stage myelodysplastic syndrome [MDS] or chronic lymphocytic leukemia [CLL]) are eligible. Basal cell cancer and carcinoma in situ treated with local excision alone do not qualify for inclusion
- Presence of symptomatic infection, defined by fever (temperature [T] >= 38 degrees Celsius [C]) OR respiratory symptoms (cough, nasal congestion, or shortness of breath) OR lung infilitrates on chest X-ray or CT imaging. Diagnosis of COVID-19 is based on polymerase chain reaction (PCR) testing of respiratory samples.
- Age equal to >= 18 years or older (children are excluded because COVID-19 typically has a milder course in children, and lack of safety data of this regimen in children)
- Platelet >= 75,000/uL
- Hemoglobin >= 9 g/dL
- Hematocrit >= 27%
- Absolute neutrophil count (ANC) >= 1000/uL
- Creatinine clearance >= 50 mL/min (Cockcroft-Gault Equation-note: plasma creatine instead of serum is used at Roswell Park)
- Total bilirubin =< 2 X institutional upper limit of normal (ULN)
- Aspartate transaminase (AST) (plasma) and alanine transferase (ALT) (plasma) =< 2 X institutional ULN
- Plasma amylase and lipase =< 2 X institutional ULN
- In the absence of COVID-19, a life expectancy of 6 months is expected
- Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
- NOTE: For blood chemistry labs, Roswell Park clinical blood chemistries are performed on plasma unless otherwise indicated
EXPANSION COHORT: Patients with cancer or allogeneic stem cell transplant recipients with and without a cancer diagnosis
- Patients with cancer may be on active therapy or received therapy (e.g., chemotherapy, radiation or surgery) within 7 years
- Patients with active cancer who have not yet been treated (e.g. newly diagnosed cancer or early stage MDS or CLL) are eligible
- Basal cell cancer and carcinoma in situ treated with local excision alone do not qualify for inclusion
- Presence of symptomatic infection, defined by fever (T >= 38.0 degrees C ) OR respiratory symptoms (cough, nasal congestion, or shortness of breath) OR lung infiltrates by chest X-ray or CT imaging. Diagnosis of COVID-19 is based on PCR testing of respiratory samples. Severe infection is excluded
- Age equal to >= 18 years or older (children are excluded because COVID-19 typically has a milder course in children, and lack of safety data of this regimen in children). In the absence of COVID-19, a life expectancy of 6 months is expected
- Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure. There may be specific instances when the patient can't provide informed consent, e.g. they require mechanical ventilation and are sedated, in which case a health care proxy will be able to provide informed consent. Patients with temporary cognitive impairment will be consented once their capacity has returned. Patients with chronic cognitive impairment, e.g. dementia, that precludes informed consent will not be enrolled.
Exclusion Criteria:
- EXCLUSION CRITERIA (MAIN COHORT):
- Patients with severe COVID-19 infection defined by pulmonary infiltrates on chest x-ray or computed tomography (CT) imaging plus one of the following: room air oxygen saturation (SaO2) =< 92%, room air partial pressure of oxygen (PaO2) < 70 mm Hg, or partial pressure of oxygen in arterial blood (PaO2)-PaO2 (alveolar gas) >= 35 mm Hg
- Contraindication to recombinant (r)-INFalpha based on prior hypersensitivity, autoimmune hepatitis, decompensated liver disease
- Patients who have active acute myeloid leukemia or acute lymphoid leukemia or are allogeneic hematopoietic stem transplant recipients. Acute leukemia in remission and chronic leukemias are not exclusion criteria
Cardiac events:
- Acute coronary syndrome, myocardial infarction, or ischemia within past 3 months
- New York Heart Association classification of III or IV congestive heart failure
- Unwilling or unable to follow protocol requirements
- Patients with known serious mood disorders
- Any additional condition, such as pre-existing inflammatory lung disease, which in the investigator's opinion deems the participant an unsuitable candidate to receive the study drugs
- Concurrent infections, e.g. bacterial pneumonia or sepsis, that would make it difficult to evaluate clinical response to therapy or study drug toxicities
- Therapies known to cause cytokine release syndrome (CRS), e.g. engineered T cells, within 30 days
- Patients at high risk for tumor lysis syndrome
- Concurrent active pneumonitis predating COVID-19, such as from checkpoint inhibitor therapy, chemotherapy-associated toxicity, or radiation pneumonitis
- Autoimmune disease that requires systemic immunosuppression
- Protocol-defined baseline abnormalities in cell counts, renal, or hepatic function
- Any additional condition which in the investigator's opinion deems the participant an unsuitable candidate to receive the study drugs
- EXCLUSION CRITERIA: EXPANSION COHORT:
- Patients with respiratory failure requiring mechanical ventilation with FIO2 of > 60%.
- Allogeneic hematopoietic stem cell transplant recipients with active pulmonary graft versus host disease (GvHD) (any grade)
Cardiac events:
- Acute coronary syndrome, myocardial infarction, or ischemia within past 3 months,
- New York Heart Association classification of III or IV congestive heart failure
- Unwilling or unable to follow protocol requirements
- Any additional condition which in the investigator's opinion deems the participant an unsuitable candidate to receive the study drugs
- Cognitively impaired adults/adults with impaired decision-making capacity
- Individuals who are not yet adults (infants, children, teenagers)
- Pregnant women
- Prisoners
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm I (rintatolimod, recombinant interferon alfa-2b)
Patients receive rintatolimod IV over 2.5-3 hours and recombinant interferon alfa-2b IV over 20 minutes on day 1 and on day 3 (or 4) in the absence of disease progression or unacceptable toxicity.
|
Given IV
Other Names:
Given IV
Other Names:
|
Active Comparator: Arm II/IV (standard of care)
Patients receive standard of care.
|
Receive standard of care
Other Names:
|
Experimental: Arm III (rintatolimod)
Patients receive rintatolimod IV over 2.5-3 hours once.
|
Given IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events (AEs)
Time Frame: Up to 30 days post treatment intiation
|
This refers to the frequency of grade 3 or 4 AEs considered to be probably or definitely related to the treatment regimen.
Toxicity will be assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE version [v] 5.0).
|
Up to 30 days post treatment intiation
|
Kinetics of viral load
Time Frame: Up to 14 days post treatment initiation
|
Will be assessed as cycle threshold values in nasopharyngeal swabs based on quantitative polymerase chain reaction (PCR) in the course of treatment and days 7 and 14.
|
Up to 14 days post treatment initiation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical efficacy
Time Frame: Up to 30 days post treatment initiation
|
Will be assessed by the frequency of these complications: (i) progression of infection requiring hospitalization; (ii) respiratory failure requiring mechanical ventilation (primary efficacy endpoint); and (iii) death within 30 days.
If present, acute respiratory distress syndrome will be graded by Berlin criteria.
|
Up to 30 days post treatment initiation
|
Kinetics of viral load
Time Frame: Up to 14 days post treatment initiation
|
Will be assessed as cycle threshold values in the peripheral blood and nasopharyngeal swab based on quantitative PCR in the course of treatment and days 7 and 14.
|
Up to 14 days post treatment initiation
|
Kinetics of changes of the immune subsets and circulating inflammatory mediators in peripheral blood
Time Frame: Baseline up to day 14 post treatment initiation
|
The circulatory inflammatory mediators include C-reactive protein (CRP), cytokines, chemokines, interferons.
|
Baseline up to day 14 post treatment initiation
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Known mediators of antiviral immunity
Time Frame: Up to 30 days post treatment initiation
|
Will assess the induction of known mediators of antiviral immunity that include (myxovirus resistance gene, MxA; protein Kinase R; oligoadenylate synthetase-2; RNAse-L, IFN-stimulated gene-15 (ISG15); IFN-induced proteins with tetratricopeptide repeats, and IFN-inducible transmembrane protein 3, TLR3, RIG-I, MDA5, IRF3, IRF7, in nasopharyngeal swabs material and blood cells of patients on all tiers of treatment.
Will also assess the expression of ACE2 (receptor for severe acute respiratory syndrome coronavirus 2 [SARS-Cov-2] entry) and potentially other genes involved in SARS-CoV-2 infection will be tested in nasopharyngeal samples.
|
Up to 30 days post treatment initiation
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Brahm H Segal, Roswell Park Cancer Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Occupational Diseases
- Neoplasms
- COVID-19
- Laboratory Infection
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antiviral Agents
- Antineoplastic Agents
- Immunologic Factors
- Interferons
- Interferon-alpha
- Interferon alpha-2
- poly(I).poly(c12,U)
Other Study ID Numbers
- I 659920 (Other Identifier: Roswell Park Cancer Institute)
- P30CA016056 (U.S. NIH Grant/Contract)
- NCI-2020-02317 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematopoietic and Lymphoid Cell Neoplasm
-
University of California, San FranciscoLazarex Cancer FoundationTerminatedHematopoietic and Lymphoid Cell Neoplasm | Malignant NeoplasmUnited States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI); Oregon Health and Science UniversityRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Mayo ClinicRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterWithdrawnHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
Clinical Trials on Best Practice
-
Emory UniversityNational Cancer Institute (NCI); National Center for Complementary and Integrative...RecruitingLymphoma | Multiple MyelomaUnited States
-
University of Massachusetts, WorcesterUniversity of FloridaEnrolling by invitationAtrial FibrillationUnited States
-
University of California, San FranciscoCompleted
-
Sunnybrook Health Sciences CentreCanadian Institutes of Health Research (CIHR); Institute for Clinical Evaluative... and other collaboratorsCompletedHypertension | Diabetes | Ischemic Heart DiseaseCanada
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)Not yet recruitingHypertension | Primary Aldosteronism | Hyperaldosteronism | Resistant Hypertension | Mineralocorticoid Excess | Secondary HypertensionUnited States
-
University of North Carolina, Chapel HillNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingDiabetes Mellitus, Type 2United States
-
Marmara UniversityUnknown
-
University of UtahRecruitingAnemia | Thrombocytopenia | Coagulopathy, Mild | HypofibrinogenemiaUnited States
-
Geisinger ClinicCompletedHypercholesterolemia | Hypercholesterolemia, Familial | Hypercholesteremia in Children | Hyperlipidemia in ChildrenUnited States
-
St. Antonius HospitalDutch Cancer SocietyUnknownPancreatic Neoplasms | Pancreatic Cancer | Pancreatic Diseases | PancreatitisNetherlands